SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (165)12/22/2005 7:45:19 PM
From: tuck  Respond to of 332
 
I'm sure AZN has at least seen the manuscript of the long awaited paper that included ALL the data from the controversial CART II study. Supposedly publication of that will be coming any day, now.

I agree the stocks remains highly binary, and my strategy for dealing with it hasn't changed. I managed to roll up my hedge without leaving TOO much money on the table (could have done better), so I'm happy enough about the day's action.

Cheers, Tuck



To: Miljenko Zuanic who wrote (165)12/23/2005 1:04:24 AM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 332
 
Does anyone know are this $50M repayable IF ARISE trial failed?

According to Thursday’s CC, there are cancellation terms in the event that ARISE fails, but the details will not be disclosed. I think it’s reasonable to infer that some—but not all—of the up-front money is returnable upon a breakup.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News